Virginia Commonwealth University

AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress

Retrieved on: 
четверг, мая 30, 2024
Medical Devices, Health, Technology, Surgery, Other Health, Artificial Intelligence, Patient, Doctor of Philosophy, DNA, Intelligence, KOAR, Transplant, GEP, Risk, DGF, Heart, Recovery, Lung transplantation, Artificial intelligence, Virginia Commonwealth University, AI, Caregiver, Biopsy, Cancer, Kidney transplantation, ATC, Kidney, Medicine, Abstract, Period, KTR, Molecular diagnostics, MAS, Heart transplantation, Cardiology, Dentistry

The findings highlight innovative approaches, including AI integration, and the real-world clinical utility of CareDx’s solutions, emphasizing their significant impact on patient care and outcomes in kidney, heart, and lung transplantation.

Key Points: 
  • The findings highlight innovative approaches, including AI integration, and the real-world clinical utility of CareDx’s solutions, emphasizing their significant impact on patient care and outcomes in kidney, heart, and lung transplantation.
  • “The additive value of artificial intelligence to our transplant solutions holds significant promise,” said John W. Hanna, CareDx President and CEO.
  • Characterization of GEP and dd-cfDNA Profile with Long-Term Malignancy Risk Post-Cardiac Transplant, L. Chen, D. H. Lee, E. Czinn, et al.
  • The integration of AI in predicting rejection risk marks a significant leap forward in patient care," said Kiran Khush, MD, MAS, Cardiologist, Professor of Cardiovascular Medicine, Stanford Medicine.

Clarametyx Biosciences Appoints Renowned Experts to Augment Strategic and Scientific Advisory Boards

Retrieved on: 
вторник, мая 28, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Biogen, Shionogi, Annamalai University, General partnership, Genentech, Biochemistry, Sarepta Therapeutics, Takeda Oncology, Biofilm, Flagship Pioneering, Palani, University, Therapy, Virginia Commonwealth University, Infection, MBA, Biophysics, MD, Takeda Pharmaceutical Company, Executive, Management

Dr. Palaniappan previously served as the Executive Vice President and Chief Technology Officer at Aruvant Sciences.

Key Points: 
  • Dr. Palaniappan previously served as the Executive Vice President and Chief Technology Officer at Aruvant Sciences.
  • His early career included leadership positions at Millennium Pharmaceuticals (acquired by Takeda), Biogen, Nexstar Pharmaceuticals (acquired by Gilead), and Par Pharmaceuticals.
  • He is currently a Managing Partner and Co-Founder of Trekk Venture Partners and serves on multiple public and private company boards.
  • Mr. Westberg received his MBA from the University of California, Berkeley and his BA from the University of California, San Diego.

Southeastern Society of Oral and Maxillofacial Surgeons Honors Dr. Ray Lee with Frank DiPlacido Humanitarian Service Award

Retrieved on: 
среда, мая 22, 2024
DDS, Patient, Biology, Hope, Sleep, Friends, Fracture, Chronic pain, Virginia Commonwealth University, Research, College, OSA, Frank, Injury, Oral and maxillofacial surgery, American Dental Association, Veteran, Family, OMS, Dentistry

Oral Surgery Management ( USOSM ) congratulates its surgeon partner N. Ray Lee , DDS, of Oyster Point Oral & Facial Surgery on receiving the Frank DiPlacido Humanitarian Service Award.

Key Points: 
  • Oral Surgery Management ( USOSM ) congratulates its surgeon partner N. Ray Lee , DDS, of Oyster Point Oral & Facial Surgery on receiving the Frank DiPlacido Humanitarian Service Award.
  • The award, given by the Southeastern Society of Oral and Maxillofacial Surgeons (SSOMS), is not bestowed annually.
  • Dr. Lee is one of only seven people to receive the award, since its establishment in 2008.
  • “The Frank DiPlacido Humanitarian Service Award is a tremendous honor, and we’re thrilled that SSOMS has chosen to recognize Dr. Lee,” said USOSM President and CEO Richard Hall.

RBB Bancorp New Chair of the Board

Retrieved on: 
среда, мая 15, 2024
Banking, Professional Services, Finance, Information technology, CFO, Royal Business Bank, Compensated emancipation, Weather, Disclosure, Community, Financial Accounting Standards Board, Chairperson, Consumer protection, Dow Chemical Company, Climate change, Senior management, Security, Chemical engineering, Corporate governance, California Department, Marketing, Earthquake, Annual report, Pandemic, FRB, FDIC, Federal Deposit Insurance Corporation, Insurance, Failure, Risk, Harvard Business School, Terrorism, Update, SBA, Community Reinvestment Act, Virginia Commonwealth University, Bank, Acquisition, Management

RBB Bancorp (NASDAQ:RBB) and its subsidiaries, Royal Business Bank (the “Bank”) and RBB Asset Management Company (“RAM”), collectively referred to herein as “the Company,” announced that at their Organizational Board of Director meetings held on May 15, 2024, after the Company annual shareholder meeting, Ms. Christina Kao has been unanimously appointed as the new Chair of the Board for the Company.

Key Points: 
  • RBB Bancorp (NASDAQ:RBB) and its subsidiaries, Royal Business Bank (the “Bank”) and RBB Asset Management Company (“RAM”), collectively referred to herein as “the Company,” announced that at their Organizational Board of Director meetings held on May 15, 2024, after the Company annual shareholder meeting, Ms. Christina Kao has been unanimously appointed as the new Chair of the Board for the Company.
  • Dr. James Kao, Chair of the Board for the past three years of RBB Bancorp and the Bank, will remain on the Boards of Directors and serve as chair of the new Enterprise Risk Committee.
  • I would like to express my sincere appreciation to all employees, the members of the Board of Directors, and Management Team members for their contributions.
  • RBB Bancorp is a community-based financial holding company headquartered in Los Angeles, California.

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
четверг, мая 9, 2024
MASH, University, Patient, Cirrhosis, Research and development, Liver disease, EASL, Safety, Hypertriglyceridemia, Administration, Journal of Clinical Pathology, Hepatology, Virginia Commonwealth University, PRIME, European Medicines Agency, Liver, Enrollment, EMA, Fibrosis, Division, SAN, Pharmaceutical industry

SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the first quarter ended March 31, 2024.
  • These key clinical developments, coupled with our agreement for commercial supply, are designed to strategically enhance our readiness for potential commercialization."
  • ENLIGHTEN-Cirrhosis, the second trial in the program, is planned to evaluate patients with compensated cirrhosis and is expected to initiate in the second quarter of 2024.
  • As of March 31, 2024, 89bio had cash, cash equivalents and marketable securities of approximately $562.3 million.

Virginia Credit Union Awards $150,000 in College Scholarships

Retrieved on: 
вторник, мая 7, 2024
George Mason University, University, East Carolina University, James Madison University, Thiel College, Columbia University, Randolph–Macon College, Barnard College, Virginia Commonwealth University, Susquehanna University, College, Longwood University, Hampden–Sydney College, Virginia Tech, Howard University, Old Dominion University, Shenandoah University, Nursing

“At VACU, we help members live more confidently, and for some members that journey includes the pursuit of a college education,” said Virginia Credit Union President/CEO Chris Shockley. “Education drives many of our most important member and community initiatives -- from our nationally recognized financial education programs to partnerships with our local schools to member engagement efforts like our scholarship program.”

Key Points: 
  • Johnnae Davis, planning to attend Virginia Tech.
  • Carter Dean, planning to attend either James Madison University or Hampden-Sydney College.
  • Christian Forrest, planning to attend Randolph-Macon College or Shenandoah University.
  • Dylan McIlwain, planning to attend the College of William & Mary.

John Patton, Head of Kindeva Drug Delivery’s Scientific Advisory Board, Named Winner of RDD Conference’s Charles G. Thiel Award

Retrieved on: 
среда, мая 8, 2024
Biotechnology, Manufacturing, Other Health, Health, General Health, Pharmaceutical, Other Science, Medical Devices, Research, Other Manufacturing, Science, School, SAB, Insulin, Publication, Infection, Pharmacy school, Conference, Virginia Commonwealth University, Multimedia, RDD, Inhalation, Pharmaceutical industry

At the recent Respiratory Drug Delivery (RDD) Conference, John Patton , Ph.D., biotechnology scientist and entrepreneur and Head of the Scientific Advisory Board (SAB) for Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, was announced as the winner of the Charles G. Thiel Award .

Key Points: 
  • At the recent Respiratory Drug Delivery (RDD) Conference, John Patton , Ph.D., biotechnology scientist and entrepreneur and Head of the Scientific Advisory Board (SAB) for Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, was announced as the winner of the Charles G. Thiel Award .
  • View the full release here: https://www.businesswire.com/news/home/20240508931671/en/
    Biotechnology scientist and entrepreneur and Kindeva Drug Delivery’s Head of the Scientific Advisory Board, John Patton (second from the left), was named the winner of the Charles G. Thiel Award for outstanding research and discovery in respiratory drug delivery at this year’s Respiratory Drug Delivery (RDD) Conference.
  • Also pictured (from left to right): Michael Hindle, Ph.D., Professor, School of Pharmacy at Virginia Commonwealth University, Stephen Stein, Scientific Director of Inhalation Product Development at Kindeva, and Milton Boyer, CEO at Kindeva.
  • John has made and continues to make a tremendous contribution to both Kindeva and the wider industry.

Doug Brown, Senior Vice President of Value & Access, COEUS, Appointed by the Government Accountability Office to the Medicaid and CHIP Payment and Access Commission (MACPAC)

Retrieved on: 
среда, мая 8, 2024
Professional Services, Public Policy, Government, Health, Healthcare Reform, Health Insurance, Managed Care, Consulting, Congress, University, Pharmacy, Comptroller, Woman, State, Policy, Dodaro, Human services, Business administration, Act, Pharmacist, Knowledge, Virginia Commonwealth University, Senior, Access, CHIP, Medicare, Data analysis, MBA, Ferdinand Magellan, Pharmaceutical industry

COEUS is pleased to announce that Doug Brown, the company’s Senior Vice President of Value and Access, has been appointed to the Medicaid and CHIP Payment and Access Commission (MACPAC).

Key Points: 
  • COEUS is pleased to announce that Doug Brown, the company’s Senior Vice President of Value and Access, has been appointed to the Medicaid and CHIP Payment and Access Commission (MACPAC).
  • “The men and women who serve on this commission bring an impressive level of knowledge and experience to advise Congress on Medicaid and the Children’s Health Insurance Program,” Dodaro said.
  • Verlon Johnson has also been named the Commission’s Chair, and Robert Duncan will continue as the Vice Chair.
  • Doug Brown, RPh, MBA, is Senior Vice President of Value and Access at COEUS, with over 30 years of pharmacy management experience.

Henry Stoever Submits Top 3 Recommendations for Education to Former Under Secretary of State's Krach Institute for Tech Diplomacy

Retrieved on: 
среда, мая 8, 2024
Education, Advisory Council, Brandeis University, Baylor University, Security Commission, Arizona State University, Purdue University, SWOT, DocuSign, Research, Economic growth, James Madison University, North Dakota University System, University Foundation, Virginia Commonwealth University, Environment, Commissioner, Judgement, Intellectual property, Kansas State University, Create, Management

CHICAGO, May 8, 2024 /PRNewswire/ -- Brentwood Advisory Group, the leading team of experienced executives that provides a broad array of board of director and executive-level services with and for its clients, today announced that its Principal Henry Stoever who serves as the Commissioner for Education for the Global Tech Security Commission (GTSC) shared recommendations made to the Honorable Keith Krach, Chairman of the Krach Institute for Tech Diplomacy (KITD) and Co-Chair of the GTSC.

Key Points: 
  • Stoever serves as an Advisory Council member for the KITD focused on ensuring that trusted technology advances freedom.
  • These SWOT analyses enabled Commissioner Stoever's Council to discuss, frame, and prioritize their recommendations to help ensure trusted technology advances freedom through education.
  • The outcome of the Education Advisory Council for the Global Tech Security Commission was to inform the Krach Institute for Tech Diplomacy's Global Tech Security Strategy and its forthcoming Tech Diplomacy Academy.
  • While being attentive to protecting intellectual property (IP) created by research universities, safeguarding research assets, and restricting tech transfer,
    b.

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

Retrieved on: 
среда, мая 8, 2024
Congress, Cirrhosis, Liver disease, EASL, Hepatic encephalopathy, MD, Virginia Commonwealth University, Patient, Sarcopenia

SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver ("EASL") Congress, to take place June 5 to 8, 2024 in Milan, Italy.

Key Points: 
  • SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver ("EASL") Congress, to take place June 5 to 8, 2024 in Milan, Italy.
  • Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy ("HE") in patients with cirrhosis: a 52-week phase 2 randomized clinical trial
    Dr. Arun J. Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University